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Abstract: 
The association between consumption of genistein-containing soybean products and lower risk of breast cancer 
suggests a cancer chemopreventive role for genistein. Consistent with this suggestion, exposing cultured human 
breast cancer cells to genistein inhibits cell proliferation, although this is not completely understood. To better 
understand how genistein works, the ability of genistein to induce apoptosis was compared in phenotypically 
dissimilar MCF-7 and MDA-MB-231 human breast cancer cells that express the wild-type and mutant p53 
gene, respectively. After 6 days of incubation with 50 µM genistein, MCF-7 but not MDA-MB-231 cells, 
showed morphological signs of apoptosis. Marginal proteolytic cleavage of poly-(ADP-ribose)-polymerase and 
significant DNA fragmentation were also detected in MCF-7 cells. In elucidating these findings, it was 
determined that after 2 days of incubation with genistein, MCF-7 but not MDA-MB-231 cells, had significantly 
higher levels of p53. Accordingly, the expression of certain proteins modulated by p53 was studied next. Levels 
of p21 increased in both of the genistein-treated cell lines, suggesting that p21 gene expression was activated 
but in a p53-independent manner, whereas no significant changes in levels of the pro-apoptotic protein, Bax, 
were found. In MCF-7 cells, levels of the anti-apoptotic protein, Bcl-2, decreased slightly at 18-24 h but then 
increased considerably after 48 h. Hence, the Bax:Bcl-2 ratio initially increased but later decreased. These data 
suggest that at the genistein concentration tested, MCF-7 cells in contrast to MDA-MB-231 cells were sensitive 
to the induction of apoptosis by genistein, but Bax and Bcl-2 did not play clear roles. 
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Article: 
Breast cancer is the second most common cause of death among all forms of cancer in women [Parker et al., 
1997], which has made the prevention and treatment of breast cancer a major health issue and healthcare goal. 
Many of the present breast cancer chemopreventive and chemotherapeutic agents can have undesirable side 
effects. For example, treatment with the non-steroidal anti-estrogenic drug, tamoxifen, is associated with 
increased risk of endometrial cancer [Smith et al., 2000]. Therefore, there has been increasing interest in using 
natural alternative substances to prevent or treat breast cancer without the side effects. In particular, 
genistein (5,7,4'-trihydroxyisoflavone), which is a phenolic phytochemical that is found in soybean products in 
high amounts, has been examined closely. 
 
The suspicion of an anti-breast cancer effect of genistein comes from epidemiological studies [Nomura et al., 
1978; Hirayama, 1981; Ingram et al., 1997, Wu et al., 1998] that have linked diets rich in soybean products with 
lower incidences of breast cancer. Furthermore, animal studies [Baggott et al., 1990; Barnes et al., 1990] have 
established that feeding soy-based diets to rats reduces chemical carcinogen- induced formation of mammary 
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tumors. Taken together, these findings have led to the general speculation that genistein is the primary soybean 
phytochemical that has anti-breast cancer activity. However, to advance the notion of genistein as a potential 
breast cancer chemopreventive agent, cellular studies have been conducted as well. For example, genistein 
inhibited the growth of cultured human breast cancer cells [Fioravanti et al., 1998; Shao et al., 1998]. This 
inhibitory effect of genistein is attributed to the induction of cell cycle arrest and/or apoptosis, although full 
characterization of the molecular events has not been completed. 
 
Apoptosis is essential for normal physiological development but also critical in eliminating any abnormal cells 
that result after exposure to genotoxic or DNA-damaging agents. In response to the DNA damage, levels of p53 
tumor suppressor protein become elevated which triggers cell cycle arrest to permit DNA repair. On the other 
hand, if the DNA damage is irreparable, the genetic program for apoptosis is activated, and eventually, the 
affected cells are eliminated in an orderly and controlled manner [Ding and Fisher, 1998]. These basic 
phenomena have been exploited in devising strategies to kill cancer cells, thus providing the basis of some 
forms of cancer chemotherapy [Fisher, 1994]. 
 
Previously, it was demonstrated that genistein induced protein-linked DNA damage in leukemia cells, 
[Markovits et al., 1989]. More recently, it was reported that genistein induced DNA damage or strand breakage 
in colon cancer cells [Salti et al., 2000]. It is thought that genistein-induced DNA damage is due to inhibition of 
DNA topoisomerase II, which is known to result in double-strand breaks in DNA [Malonne and Atassi, 1997]. 
Therefore, it is conceivable that such DNA damage induced by genistein can initiate multiple events leading to 
apoptosis. That is, there may be elevation in the levels of p53, which is a transcription factor for numerous 
genes including some involved in apoptosis [Fields and Jang, 1990]. For example, WAF1(p21) [El-Deiry et al., 
1993], which halts cell cycle progression by inhibiting cyclindependent kinases, and Bax [Miyashita and Reed, 
1995], which promotes apoptosis, are two genes that are transcriptionally activated by p53. On the other hand, 
p53 suppresses the transcription of other genes [Mack et al., 1993] such as Bcl-2 [Miyashita et al., 1994; 
Budhram-Mahadeo et al., 1999], which is an anti-apoptotic factor. Accordingly, increased levels of p21 protein 
would stimulate cell cycle arrest that may be followed by apoptosis, which typically happen when cells sustain 
DNA damage [El-Deiry et al., 1994]. Then too, the subsequent increase in Bax and decrease in Bcl-2 protein 
levels would promote apoptosis [Oltvai et al., 1993]. Other apoptotic events might also occur such as caspase-
mediated cleavage of the DNA repair enzyme, poly-(ADP-ribose)-polymerase (PARP) [Kaufmann et al., 1993; 
Duriez et al., 1997], and fragmentation of DNA [Pandey et al., 1994] by a caspase-activated deoxyribonuclease 
[Enari et al., 1998]. 
 
Because genistein induces DNA double-strand breaks [Markovits et al., 1989; Salti et al., 2000] which could 
lead to p53-mediated apoptosis, we compared the capacity of genistein to induce apoptosis in phenotypically 
dissimilar MCF-7 and MDA-MB-231 human breast cancer cells that express the wild-type and mutant p53 
gene, respectively. We determined if the p53 gene status of human breast cancer cells influences the ability of 
genistein to induce the expression of several relevant molecular markers related to apoptosis. 
 
MATERIALS AND METHODS 
 
Genistein, camptothecin, doxorubicin, ethidium bromide, normal and low melting point agarose products, 
trypsin, Eagle's minimum essential medium and Leibovitz's L-15 medium were purchased from Sigma 
Chemical Co. (St. Louis, MO). Fetal bovine serum (FBS) was purchased from BioWhittaker, Inc. (Walkersville, 
MD). Antibiotics were purchased from Mediatech, Inc. (Herndon, VA) as a stock solution (10,000 U/ml 
penicillin G, 10,000 µg/ ml streptomycin, 25 µg amphotericin B). MCF-7 and MDA-MB-231 human breast 
cancer cell lines were purchased from American Type Culture Collection (ATCC) (Rockville, MD). These 
distinct cell lines, which are adherent and have epithelial morphology when cultured, originated from separate 
mammary gland adenocarcinomas present in two different female Caucasians. The cells were obtained from the 
adenocarcinomas of the human subjects by pleural effusion. As characterized by others [Elstner et al., 1995; Liu 
et al., 1997], MCF-7 cells express estrogen receptors and wild-type p53 gene and are also minimally invasive. 
MDA-MB-231 cells are estrogen receptor-negative, expressive mutant p53 gene, and are highly invasive or 
metastatic. 
 
SDS-PAGE mini-gels (4-20% Tris-Glycine), See-Blue prestained protein markers, running buffer (10x) were 
purchased from Novex (San Diego, CA). The Hybond ECL nitrocellulose membrane was purchased from 
Amersham Life Science (Arlington Heights, IL). The mouse monoclonal anti-p53 antibody (clone BP53-12) 
was purchased from Sigma Chemical Co. (St. Louis, MO). The mouse anti-WAF1 /p21 monoclonal antibody 
(clone EA10) and rabbit anti-bax polyclonal antibody were purchased from Oncogene Research Products 
(Cambridge, MA). The mouse anti-bcl-2 antibody (clone BCl-2-100) was purchased from Zymed Laboratories 
Inc. (San Francisco, CA). The rabbit anti-PARP polyclonal antibody (clone VIC5) was purchased from Roche 
Molecular Biochemicals (Indianapolis, IN). 
 
Cell Culture 
MCF-7 and MDA-MB-231 cells were routinely maintained in complete Eagle's minimum essential medium and 
Leibovitz's L-15 medium, respectively, as recommended by ATCC. The cell culture media were each 
supplemented with 10% FBS, 1% penicillin G/streptomycin, and 0.2% amphotericin B. MCF-7 cells were 
cultured at 37°C in a humidified atmosphere of 95% air/5% CO2 and subcultured once a week at a ratio of 1:5. 
MDA-MB-231 cells were cultured at 37°C in a humidified atmosphere of 100% air and subcultured once a 
week at a ratio of 1:25. Cell culture medium was renewed 2-3 times/ week. 
 
Morphological Examination of Cells After Treatment With Genistein 
On the second day after seeding, MCF-7 and MDA-MB-231 cells (1 x 10
6
 cells/ml) were incubated for 0-72 h 
with 0 and 50 µM of genistein dissolved in DMSO. The final concentration of DMSO was 0.1% in both 
genistein-treated and untreated control cells. The cells were examined with an Olympus IX-70 inverted 
microscope equipped with PM-C35DX camera. 
 
Detection of Poly-(ADP-Ribose)-Polymerase (PARP) Cleavage in Cells After Treatment With Genistein 
MCF-7 (7.5 x 10
5
 cells/10 ml) and MDA-MB231 cells (1.5 x 10
5
 cells/10 ml) were incubated for 0-12 days with 
50 µM of genistein dissolved in DMSO. Cells treated with 0.1% DMSO were used as a negative vehicle 
control. MCF-7 cells treated with 0.4 µg/ml camptothecin for 24 h were used as a positive control. All cells 
were treated on the second day after seeding. 
 
To harvest the cells, they were washed with Ca
2+
/Mg
2+
-free Hank's Balanced Salt Solution (HBSS) once and 
detached with 0.25% trypsin/ 0.03% EDTA in HBSS. After trypsinization, cells were pelleted at 300 x g for 10 
min, and the cell pellets were washed with phosphate buffered saline (PBS) once. Then, the cells were 
suspended in lysis buffer (50 mM KCl, 0.5% NP- 40, 25 mM HEPES (pH 7.8),1 mM PMSF, 10 µg/ ml 
leupeptin, 20 µg/ml aprotinin, 100 µM DTT) and left on ice for 4 min. The above cell lysates were centrifuged 
at 16,000g for 1 min. The nuclei-containing cell pellets were washed once with buffer (50 mM KCl, 25 mM 
HEPES (pH7.8), 1 mM PMSF, 10 µg/ml leupeptin, 20 µg/ml aprotinin, 100 µM DTT) and then resuspended in 
nuclear extraction buffer (500 mM KCl, 10% glycerol, 25 mM HEPES (pH 7.8), 1 mM PMSF, 10 µg/ml 
leupeptin, 20 µg/ml aprotinin, 100 µM DTT) and left on ice for 30 min. After centrifugation, the supernatant 
was collected and saved as the nuclear extract. 
 
The proteins in the nuclear extract (50 µg) were separated by SDS-PAGE and blotted to a nitrocellulose 
membrane. The nitrocellulose membrane containing the transferred proteins was then blocked with 5% non-fat 
milk. Next, the membrane was probed with rabbit antiPARP primary antibody and corresponding goat anti-
rabbit secondary antibody conjugated to horseradish peroxidase. The nitrocellulose membrane was then 
incubated with chemiluminescent developing reagent for 1 min and then exposed to X-ray film. The presence of 
PARP protein and cleaved products was then visualized by developing the film. 
 
Determination of DNA Fragmentation in Cells After Treatment With Genistein 
MCF-7 (7.5 x 10
5
 cells/10 ml) and MDA-MB231 cells (1.5 x 10
5
 cells/10 ml) were treated for 72 h with 50 µM 
of genistein dissolved in DMSO. Cells treated with 0.1% of DMSO were used as a negative vehicle control. 
MCF-7 and MDA-MB231 cells treated with 0.4 µg/ml camptothecin for 24 h were used as a positive control. 
All cells were treated on the second day after seeding. 
 
After treatment, cells were detached by trypsinization and harvested. DNA fragmentation was determined using 
the Cell Death Detection ELISA kit (Roche Molecular Biochemicals, Indianapolis, IN). Briefly, 5 x 10
4
 cells/ 
sample were suspended for 30 min on ice in 500 µl of solubilization buffer, which destroys the plasma 
membrane of cells without disturbing the nuclear membrane. Afterwards, the lysate was centrifuged at 16,000g 
at 4°C for 10 min. The supernatant, which contains any low molecular weight DNA fragments resulting from 
apoptosis, was collected. To quantify the DNA fragments, a microtiter plate was first coated with anti-histone 
antibody and then incubated with the supernatant to allow binding of any mono- and oligonucleosomes to the 
anti-histone antibody. Next, the microtiter plate was incubated with anti-DNA-peroxidase-labeled antibody, 
which binds to the DNA component of the nucleosomes, thus forming immunocomplexes that were quantified 
by incubating next with a peroxidase substrate (ABTS). The resulting absorbance at 405 nm against 492 nm 
were measured using a TECAN SLT 340 ATTC microtiter plate reader. 
 
Determination of p53, p21, bax, and bcl-2 Protein Expression in Cells After Treatment With Genistein 
MCF-7 (7.5 x 10
5
 cells/10 ml) and MDA-MB231 cells (1.5 x 10
5
 cells/10 ml) were treated for 0-9 days with 50 
µM of genistein dissolved in DMSO. Cells treated with 0.1% of DMSO were used as a negative vehicle control. 
MCF-7 cells treated with 0.2 µg/ml doxorubicin for 48 h were used as a positive control. All cells were treated 
on the second day after seeding. 
 
To harvest the cells, they were washed with HBSS once and detached with 0.25%trypsin/ 0.03% EDTA in 
HBSS. After trypsinization, cells were pelleted at 300 x g for 10 min, and the cell pellets were washed with PBS 
once. Then, the cells were suspended in lysis buffer (25 mM Tris Cl (pH8.0), 150 mM NaCl, 1% NP-40, 1% 
sodium deoxycholate, 0.1% SDS, 100 µg/ml PMSF, 1 mM Na3VO4, 5 µg/ml leupeptin, 5 µg/ml aprotinin, 100 
µM DTT) and left on ice for 30 min. Next, the above cell lysates were centrifuged at 16,000g for 10 min. The 
supernatant was collected as the whole cell lysates. 
 
The proteins in the whole cell lysates (50 µg) were separated by SDS-PAGE and blotted to nitrocellulose 
membrane. The membrane was then blocked with non-fat milk and probed with rabbit anti-bax primary 
antibody (1:200) and the corresponding secondary antibody (1:5000) conjugated to horseradish peroxidase. 
Next, the nitrocellulose membrane was incubated with the chemiluminescent developing reagent for 1 min and 
then exposed to X-ray film. The presence of bax protein was then visualized by developing the film. 
Afterwards, the same membrane was stripped with buffer (62.5 mM Tris Cl (pH6.8), 2% w/v SDS, 100 mM β-
mercaptoethanol) at 55°C for 30 min. The stripped membrane was reprobed with mouse anti-bcl-2 antibody 
(1:1000) and the corresponding secondary antibody (1:5000) to assess the intracellular bcl-2 levels using the 
same procedure described above. In this way, the same membrane was stripped and reprobed with mouse anti-
p21 antibody (1:100), mouse anti- p53 antibody (1:2000), rabbit anti-actin antibody (1:200), and mouse anti-
tubulin antibody (1:200). Levels of protein expression were quantified using a Bio-Rad GS-670 Imaging 
Densitometer. 
 
Data Analysis 
Data were analyzed by the one-way analysis of variance Tukey HSD multiple comparison test using the Systat 
software v9.01 (SPSS Inc., Chicago, IL). 
 
RESULTS 
 
To determine if exposing human breast cancer cells to genistein results in morphological changes characteristic 
of apoptosis, MCF-7 and MDA-MB-231 cells were incubated with 0 and 50 µM genistein for 0-6 days. After 4 
days of incubation, cell shrinkage and membrane blebbing were seen in only a limited population of the 
genistein-treated MCF-7 cells. But, after 6 days of incubation (Fig. 1), the majority of the MCF-7 genistein-
treated cell populations showed such morphological features of apoptosis. Moreover, the majority were 
detached from the culture dishes, although a small number of these cells were still attached and apparently 
viable. These viable cells were larger in size than the control cells, and they also had increased intracellular 
vacuoles upon closer examination. Thus, these visual observations suggest that genistein induced apoptosis in 
most of the individual MCF-7 cells, but differentiation in the remainder of the cells. 
 
On the other hand, most of the genisteintreated MDA-MB-231 cells were still viable, but much larger in size 
than untreated cells after 6 days of incubation (Fig. 1). Even after 12 days of exposure to genistein, no 
appreciable morphological signs of apoptosis were seen (data not shown). Instead, more than one nucleus was 
 
 
seen in many of the cells, which is a similar feature seen in some normal mammalian cells that may also be 
polyploidal [Mowat and Stewart, 1998]. The nuclei were normal or slightly smaller in size and located mainly 
in the middle of the cells. In contrast, the cytoplasm was more flat and expanded in area. Thus, these visual 
observations suggest that genistein induced differentiation but not apoptosis in MDA-MB-231 cells. 
 
To examine other markers of apoptosis, proteolytic cleavage of the nuclear protein, PARP, was assessed by 
SDS-PAGE/Western-immunoblotting analysis of MCF-7 and MDAMB-231 cells that had been incubated with 
50 µM genistein for 0-6 days (Fig. 2). In the positive control (camptothecin-treated cells), PARP cleavage was 
detected in both MCF-7 and MDA-MB-231 cells as indicated by the presence of an 89 kD band that reflects a 
proteolytic fragment of the 116 kD PARP protein. Unexpectedly, in the case of MDAMB-231 cells, slight 
presence of the 89 kD proteolytic fragment was detected in the untreated control and also DMSO-treated 
vehicle control. Moreover, genistein did not induce PARP cleavage since there was no increase in band 
intensity of the 89 kD fragment. In the case of MCF-7 cells, where the 89 kD fragment was not detected in the 
untreated control and also DMSO-treated vehicle control, genistein induced only slight PARP cleavage as 
indicated by the presence of the 89 kD fragment after 4 days of incubation. 
 
As the results of the PARP cleavage assay were not absolutely clear in assessing apoptosis, the Cell Death 
Detection ELISA was performed on both cell lines that had been exposed to 50 µM genistein for 72 h to further 
assess apoptosis. The assay detects endonuclease-mediated DNA fragmentation, a common event in apoptosis. 
As shown in Figure 3, genistein significantly increased DNA fragmentation in MCF-7 cells as indicated by the 
greater optical density readings relative to that of control cells. In contrast, genistein did not produce such an 
effect in MDA-MB-231 cells. 
 
Having established to a reasonable extent that genistein induced apoptosis at least in MCF-7 cells, we were 
prompted next to examine the expression of p53 and p21 proteins by Western analysis. Genistein had different 
 
 
effects in the two cell lines. In MCF-7 cells incubated with 50 µM genistein, p53 expression increased slightly 
at 2 h, peaked at 48-72 h, and then dropped at 6 day of incubation (Fig. 4). In contrast, there were no significant 
changes in the expression of p53 in MDA-MB-231 cells 
 
 
throughout the entire incubation period. Consistent with the increased expression of p53, genistein-treated 
MCF-7 cells also had increased expression of p21. Highest expression was found after 48 h of incubation with 
genistein with only a slight decline occurring over the next 4 days. Despite no change in the expression of p53 
in MDA-MB-231 cells, increased expression of p21 was detected after only 18 h of incubation with genistein 
and increased further with continued incubation. 
 
To consider if genistein induced apoptosis via p53-dependent modulation of Bax and Bcl-2 gene expression, we 
finally examined the expression of Bax and Bcl-2 protein levels in MCF-7 and MDA-MB-231 cells that had 
been incubated with 50 µM genistein (Fig. 5). There were no significant changes in Bax expression in either 
cell line during the entire incubation period. In MCF-7 cells, the expression of Bcl-2 decreased slightly after 18-
24 h, but then increased noticeably after 48 h of incubation with genistein. In the genistein-treated MDAMB-
231 cells, Bcl-2 expression increased slightly overall. Densitometric analysis of the expression of Bax and Bcl-2 
as a ratio is presented in Figure 6. In MCF-7 cells, the Bax:Bcl-2 ratios increased at 18-24 h of incubation with 
genistein, but then dropped to ratios lower than that in the control cells. In contrast, the Bax:Bcl-2 ratios in 
genisteintreated MDA-MB-231 cells were lower than that of the control cells. 
 
DISCUSSION 
 
Complete characterization or full elucidation of how genistein inhibits the proliferation of cultured human 
breast cancer cells has not been achieved yet. However, a partial explanation of the anti-proliferative effect of 
genistein is that this phytochemical kills the cells by inducing apoptosis. Several research groups [Constantinou 
et al., 1998; Shao et al., 1998; Li et al., 1999] have reported that incubating human breast cancer cells with 
genistein results in apoptosis. As an expansion of such previous work, our data collectively indicated that 
genistein induce apoptosis in MCF-7 cells but not in MDA-MB231 cells. This difference in sensitivity of the 
two cell lines to genistein might reflect their dissimilar phenotypes. For example, as described elsewhere 
[Elstner et al., 1995; Liu et al., 1997], MCF-7 cells express estrogen receptors 
 
 
and wild-type p53 gene and are also minimally invasive. MDA-MB-231 cells are estrogen receptor-negative, 
expressive mutantp53 gene, and are highly invasive. 
 
In assessing apoptosis in the present study, morphological examination of the cells by light microscopy and 
analysis of DNA fragmentation by the Cell Death Detection ELISA provided 
 
 
evidence of apoptosis in MCF-7 cells that had been incubated with 50 µM genistein for 6 days. The detection of 
proteolytic cleavage of PARP, which is recognized as an early marker of apoptosis, in genistein-treated MCF-7 
cells was not quite successful or revealing. Using nuclear extracts, only marginal cleavage of the nuclear 
protein, that is involved in DNA repair, i.e., PARP, was detected. Nevertheless, we also observed chromatin 
condensation after DAPI staining of MCF-7 cells that had been incubated with 50 µM genistein for 6 days (data 
not shown). Among all the methods for the detection of apoptosis, cell morphological changes, especially 
chromatin condensation, are considered the most accurate indicators of apoptosis [Willingham, 1999]. Thus, in 
the present study, evaluating several standard markers allowed better assessment of apoptosis. 
 
By comparison, our results are in partial agreement with that of a similar study with MCF-7 cells [Constantinou 
et al., 1998], where within 2 days genistein induced differentiation at concentrations of 10-45 µM, but triggered 
apoptosis at much higher concentrations of 100-300 µM. We saw MCF-7 cells initially undergoing 
differentiation after 48-72 h of incubation with 50 µM genistein, as indicated by the appearance of intracellular 
neutral lipid droplets and an increase of intracellular casein levels (data not shown). However, upon continued 
incubation with 50 µM genistein, markers of apoptosis appeared at Day 4, but at Day 6, the majority of the 
MCF-7 cells were affected. Thus, our findings have revealed that a lower concentration of genistein (i.e., 50 µM 
rather than 100-300 µM) is capable of inducing apoptosis in MCF-7 cells if the time of incubation is prolonged. 
This is more relevant to physiological conditions where small amounts of genistein in soybean products are 
ingested in the diet for a long period of time to exert a chronic health effect. 
 
Since apoptosis is often accompanied by increased expression of p53 that is thought to actually mediate the 
apoptosis [Ding and Fisher, 1998], the expression of p53 protein and also p21 protein resulting from p53-
dependent and p53-independent pathways was examined in the genistein-treated cells. Although genistein 
increased the expression of p53 in only MCF-7 cells, there was increased expression of p21 in both MCF-7 cells 
expressing wild-type p53 gene and MDA-MB-231 cells expressing mutant p53 gene. The p53 gene in MDA-
MB231 cells is deleted in one allele and mutated at lys
280
 in exon 8 in the other allele [Runnebaum et al., 1994], 
resulting in non-functional p53 protein. Therefore, our findings suggest that genistein increases the expression 
of p21 protein in MDA-MB-231 cells via a p53-independent pathway. However, the possibility cannot be ruled 
out that the increased expression of p21 protein in genistein-treated MCF-7 cells could be attributed either to 
p53-dependent or p53-independent pathways, or perhaps both. The p21 gene promoter region contains multiple 
response elements for the binding of numerous transcription factors [cartel and Tyner, 1999] and subsequent 
activation of the gene. While p53 is important for p21-mediated events, this is not always the case. For example, 
the p53- dependent activation of p21 gene transcription is critical for cellular responses to DNA damage, Neu 
differentiation factor, or ribonucleotide inhibitors. On the other hand, the p53-independent activation of p21 
gene transcription occurs in cells exposed to various agents that stimulate differentiation. These differentiation 
agents induce binding of transcription factors to specific cis-acting responsive elements, such as Sp1-3, Ap2, 
BRCA1, VDR, RAR, C/EBPα and β, STAT1, STAT3, and STAT5, in the promoter region of the p21 gene. 
Hence, it is conceivable that genistein-induced p53-independent expression of the p21 gene by activating one or 
several of the transcription factors that bind to these response elements. It must also be considered that 
regulation of p21 gene expression occurs at multiple levels, including transcription and stabilization of p21 
mRNA [Shao et al., 1998], translation of p21 mRNA [Gudas et al., 1995], and post-translational stabilization of 
p21 protein [Timchenko et al., 1996]. 
 
It is uncertain whether the increased expression of p21 is essential for the apoptosis induced in MCF-7 cells by 
genistein. As a universal inhibitor of cyclin-dependent kinases (Cdk), p21 predominately inhibits Cdk2 and 
Cdk4 during cell cycle arrest at the G1/S phase transition [Harper et al., 1995]. Additionally, p21 binds to 
proliferating cell nuclear antigen (PCNA) and blocks ongoing DNA synthesis and replication at the S phase 
[Flores-Rozas et al., 1994]. Rapid induction of p21 gene expression and cell cycle arrest can result when cells 
are starved of serum or exposed to ultraviolet radiation and other DNA-damaging agents [Harada and Ogden, 
2000]. Upon DNA damage, activation of p21 gene expression that promotes cell cycle arrest at the G1/S phase 
allows cells the opportunity to repair the damage. If DNA repair is successful, cell cycle progression will 
resume. If there is irreparable DNA damage, cells will undergo apoptosis. On the other hand, although p21 is 
important for apoptosis in some systems [Duttaroy et al., 1997], this is not always true [Gorospe et al., 1997]. 
Moreover, cells lacking p21 appear to undergo apoptosis normally [Brown et al., 1997]. In any event, a recent 
study suggests that cleavage of p21 by caspases may be required to permit cells in a state of cell cycle arrest to 
commit apoptosis [Zhang et al., 1999]. Thus, p21 may represent a unique intracellular sensor for making 
decisions regarding proliferation, cell cycle arrest, apoptosis, or differentiation. Genistein seems to influence all 
four of these processes in human breast cancer cells. 
 
Increased expression of p21 is also found when cells undergo G2/M phase arrest and upon induction of 
differentiation [Dulic et al., 1998; Zhang et al., 1999]. In our study, the increased expression of p21 protein was 
much higher in MDA-MB-231 cells than in MCF-7 cells. This finding is consistent with our other recent work 
(unpublished data), where genistein induced cell cycle arrest at the G2/M phase in both cell lines, but to a 
greater extent in MDA-MB-231 cells. Even though both MCF-7 and MDA-MB231 cells exposed to genistein 
had increased expression of p21 protein and were arrested at the G2/M phase of the cell cycle, MCF-7 cells 
committed apoptosis whereas MDA-MB-231 cells differentiated. It is unclear why the increased p21 expression 
had different end effects. 
 
Since the expression of p53 was increased by genistein in our MCF-7 cells, other p53-responsive genes besides 
p21 may be affected as well. The Bax gene is transcriptionally activated [Miyashita and Reed, 1995] and the 
Bcl-2 gene is transcriptionally suppressed [Miyashita et al., 1994; Budhram-Mahadeo et al., 1999] by p53. 
Nevertheless, the apoptosis in genistein-treated MCF-7 cells did not seem to involve the pro-apoptotic protein, 
Bax, because there was no significant change in the expression of Bax protein as determined by SDS-
PAGE/Western-immunoblotting analysis. Unexpectedly, expression of the anti-apoptotic protein, Bcl-2, 
decreased in MCF-7 cells after 18-24 h of incubation with genistein, but then increased considerably after 48 h. 
The increased expression of Bcl-2 would not be anticipated to promote apoptosis in the MCF-7 cells, but 
increased expression of Bcl-2 protein and apoptosis have been reported in normal human fibroblasts exposed to 
H2O2 [Chen et al., 2000]. Moreover, although an increased Bax:Bcl-2 ratio would be expected to promote 
apoptosis, we found only a transient increase of the Bax:Bcl-2 ratio after 18-24 h of incubation of MCF-7 cells 
with genistein that stimulated apoptosis. Later, the Bax:Bcl-2 ratio in these genistein-treated cells declined to a 
lower value than in control cells after 48 h of incubation. It is possible that the transient increase of the Bax:Bcl-
2 ratio commits the genistein-treated MCF-7 cells to apoptosis, but after the death signal is generated, the ratio 
does not need to be sustained for the execution stage of apoptosis. 
 
Besides Bax and Bcl-2, other Bcl-2 family members such as Bcl-XL, Bcl-w, Bak, and Bcl-XS may have also 
been affected in MCF-7 cells exposed to genistein. Thus, the overall ratio of the death agonists to Bcl-2 family 
of antagonists could be more critical in determining the ultimate fate of the MCF-7 cells. Additionally, the 
apoptosis in MCF-7 cells could be via a “Bcl-insensitive” apoptotic pathway such as that triggered by tumor 
necrosis factor (TNF) or Fas ligand [Strasser et al., 2000]. Bcl-2 may have a second function that is distinct 
from its ability to block apoptosis, as suggested by other research. Overexpression of Bcl-2 promotes the exit of 
stressed cells from the cell cycle and also retards quiescent G0-phase cells from re-entering the cell cycle in 
response to mitogenic stimulation [Strasser et al., 1997]. Therefore, the increased expression of Bcl-2 protein in 
our genisteintreated MCF-7 cells may help prevent cells from re-entering the cell cycle. 
 
While this work was in progress, it was reported [Li et al., 1999] that 30 µM genistein dissolved in 0.1 M 
Na2CO3 induced apoptosis, increased Bax and decreased Bcl-2 protein expression in MDA-MB-231 cells. 
These findings are obviously different than our findings. The discrepancies may be due to the use of different 
solvents to dissolve the genistein for incubation with the cells. We used the traditional solvent, DMSO, to give a 
final concentration of 0.1% in the culture media, which did not exert any effects on the measurement 
parameters. Nevertheless, we did expose our MDAMB-231 cells up to 6 days with 25-50 µM genistein 
dissolved in 0.1 M Na2CO3, but did not see any morphological signs of apoptosis although cell proliferation was 
apparently inhibited. Therefore, other factors such as differences in cell culture medium, source of purified 
genistein, and primary antibodies to detect Bax and Bcl-2 may explain the differences in results. Furthermore, it 
is possible that there could be MDA-MB-231 cells with dissimilar phenotypes as a result of the cells being 
maintained under different conditions in different laboratories, as suggested recently for MCF7 cells [Gooch 
and Yee, 1999]. 
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